MX2022013883A - Compuestos de metiltioninio para uso en el tratamiento de covid-19. - Google Patents

Compuestos de metiltioninio para uso en el tratamiento de covid-19.

Info

Publication number
MX2022013883A
MX2022013883A MX2022013883A MX2022013883A MX2022013883A MX 2022013883 A MX2022013883 A MX 2022013883A MX 2022013883 A MX2022013883 A MX 2022013883A MX 2022013883 A MX2022013883 A MX 2022013883A MX 2022013883 A MX2022013883 A MX 2022013883A
Authority
MX
Mexico
Prior art keywords
methylthioninium
compounds
covid
treatment
subject
Prior art date
Application number
MX2022013883A
Other languages
English (en)
Inventor
Michael Philip Mazanetz
Claude Michel Wischik
Mohammad Arastoo
Original Assignee
Wista Lab Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB2006659.3A external-priority patent/GB202006659D0/en
Priority claimed from GBGB2016955.3A external-priority patent/GB202016955D0/en
Application filed by Wista Lab Ltd filed Critical Wista Lab Ltd
Publication of MX2022013883A publication Critical patent/MX2022013883A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención proporciona métodos para tratar COVID-19 en un sujeto usando compuestos de metiltioninio.
MX2022013883A 2020-05-05 2021-04-30 Compuestos de metiltioninio para uso en el tratamiento de covid-19. MX2022013883A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB2006659.3A GB202006659D0 (en) 2020-05-05 2020-05-05 Therapeutic treatments
GBGB2016955.3A GB202016955D0 (en) 2020-10-26 2020-10-26 Therapeutic treatments
PCT/EP2021/061480 WO2021224144A1 (en) 2020-05-05 2021-04-30 Methylthioninium compounds for use in the treatment of covid-19

Publications (1)

Publication Number Publication Date
MX2022013883A true MX2022013883A (es) 2022-11-30

Family

ID=75801589

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022013883A MX2022013883A (es) 2020-05-05 2021-04-30 Compuestos de metiltioninio para uso en el tratamiento de covid-19.

Country Status (11)

Country Link
US (1) US20230165875A1 (es)
EP (1) EP4146223A1 (es)
JP (1) JP2023525512A (es)
KR (1) KR20230012514A (es)
CN (1) CN116056724A (es)
AU (1) AU2021267670A1 (es)
BR (1) BR112022022515A2 (es)
CA (1) CA3181393A1 (es)
MX (1) MX2022013883A (es)
TW (1) TW202200150A (es)
WO (1) WO2021224144A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202204185D0 (en) * 2022-03-24 2022-05-11 Wista Lab Ltd Oral treatment

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060264423A1 (en) 2005-05-20 2006-11-23 Bioenvision, Inc. Methylene Blue Therapy of Viral Disease
EP2013191B3 (en) 2006-03-29 2019-02-27 Wista Laboratories Ltd. 3,7-diamino-10h-phenothiazine salts and their use
HUE031633T2 (en) 2011-02-11 2017-07-28 Wista Lab Ltd Phenothiazine diaminium salts and their use
EP3826639A1 (en) * 2018-07-26 2021-06-02 WisTa Laboratories Ltd. Optimised dosage of diaminophenothiazines in populations

Also Published As

Publication number Publication date
CN116056724A (zh) 2023-05-02
AU2021267670A1 (en) 2022-12-08
TW202200150A (zh) 2022-01-01
CA3181393A1 (en) 2021-11-11
WO2021224144A1 (en) 2021-11-11
BR112022022515A2 (pt) 2022-12-13
EP4146223A1 (en) 2023-03-15
KR20230012514A (ko) 2023-01-26
US20230165875A1 (en) 2023-06-01
JP2023525512A (ja) 2023-06-16

Similar Documents

Publication Publication Date Title
MX2021010193A (es) Azepino-indoles y otros heterociclos para el tratamiento de trastornos cerebrales.
PH12018502355A1 (en) Enzyme inhibitors
MX2020001406A (es) Mavacamten para su uso en el tratamiento de la cardiomiopatia hipertrofica.
SG10201907819WA (en) N-((het)arylmethyl)-heteroaryl-carboxamides compounds as plasma kallikrein inhibitors,
MX2019007256A (es) Inhibidores de las fosfodiesterasas y métodos de tratamiento microbiano.
MX2021008191A (es) Antagonistas del péptido relacionado con el gen de calcitonina (cgrp) para el tratamiento de la irrupción de migraña.
MX2020013808A (es) Antagonista de gremlina-1 para la prevencion y el tratamiento del cancer.
MX2022001004A (es) Inhibidores de enzimas.
EA202192122A1 (ru) Соединения, обладающие активностью индуцирования ферроптоза, и способы их применения
MX2020008195A (es) Compuestos para el tratamiento del dolor.
PH12018502297A1 (en) 9-aminomethyl minocycline compounds and methods of use thereof in urinary tract infection (uti) treatment
MX2021003903A (es) Terapia combinada para el melanoma.
TN2019000211A1 (en) Antitumoral compounds
PH12020552059A1 (en) Dosing regimen for the treatment of pi3k related disorders
MX2023008193A (es) Procedimientos para tratar el cáncer.
PH12018501943A1 (en) Pharmaceutical compositions for the treatment of cancer
MX2021009863A (es) Una molecula dbait en combinacion con inhibidor de quinasa para el tratamiento del cancer.
MX2021006011A (es) Un inhibidor de la quinasa aurora a para su uso en el tratamiento del neuroblastoma.
JOP20210245A1 (ar) طرق لعلاج الداء النشواني من النوع خفيف السلسلة
MX2022000811A (es) Inhibidores de enzimas.
MX2019004804A (es) Tratamiento para el prurigo nodula.
MX2021003160A (es) Combinaciones de inhibidores de tgfbeta e inhibidores de cdk para el tratamiento de cancer de mama.
MX2021002652A (es) Uso de inhibidores de caseina-cinasa 1 para el tratamiento de enfermedades vasculares.
MX2020008881A (es) Métodos de tratamiento contra el cáncer que comprenden inhibidores de chk1.
MX2022013883A (es) Compuestos de metiltioninio para uso en el tratamiento de covid-19.